Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2014 17:09 ET | Source: Durata Therapeutics, Inc.

FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

CHICAGO, March 31, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 12...
March 14, 2014 07:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial Results

CHICAGO, March 14, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced its fourth quarter and full year 2013 financial results. "2013 was a year of incredible...
March 07, 2014 08:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Announce Full Year 2013 Financial Results on March 14, 2014

CHICAGO, March 7, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Friday, March 14th at 8:30 a.m. Eastern Time to discuss fourth quarter/full...
March 03, 2014 08:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at Upcoming Investor Conferences

CHICAGO, March 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that the members of the management team will make presentations at two upcoming...
February 18, 2014 08:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at the RBC Capital Markets' Global Healthcare Conference

CHICAGO, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the 2014 RBC Capital Markets' Global...
December 23, 2013 08:00 ET | Source: Durata Therapeutics, Inc.

European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin

CHICAGO, Dec. 23, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization...
December 03, 2013 08:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Submits Marketing Authorization Application for Dalbavancin

CHICAGO, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency...
November 26, 2013 16:15 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for Dalvance(TM) (dalbavancin hydrochloride)

CHICAGO, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that the New Drug Application (NDA) for its investigational drug, Dalvance™ (dalbavancin...
November 15, 2013 16:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference

CHICAGO, Nov. 15, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Jefferies 2013 Global Healthcare...
November 06, 2013 06:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics, Inc. Reports Third Quarter 2013 Financial Results

CHICAGO, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended September 30, 2013. Financial results for the quarter ended...